Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for breast cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Hormone Therapy
ARV-471 for Breast Cancer
Recruiting2 awardsPhase 3
East Brunswick, New Jersey
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
PI3K Inhibitor
Inavolisib + Fulvestrant vs Alpelisib + Fulvestrant for Breast Cancer
Recruiting2 awardsPhase 3
Camden, New Jersey
This trial is testing two drug combinations to find out which one is better for treating a specific type of advanced breast cancer that hasn't responded to previous treatments. The drugs work by stopping cancer cells from growing and spreading.
Antibody-drug conjugate
Dato-DXd +/− Durvalumab for Breast Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a new treatment for patients with a specific type of breast cancer who still have cancer after surgery and initial treatments. The treatment uses a drug called Dato-DXd, which targets and kills cancer cells, and may also include durvalumab, which helps the immune system fight cancer. The goal is to see if this new treatment works better than current options.
Trials With No Placebo
FES-PET/DBT Imaging for Breast Cancer
Recruiting1 awardPhase < 1
Philadelphia, Pennsylvania
This trial will assess if a novel imaging device combining PET & DBT can aid in the diagnosis of breast cancer for those 18+. Up to 20 evaluable subjects will take part and receive FES-BPET/DBT imaging, but results won't direct treatment decisions.
Hormone Therapy
ARV-471 for Breast Cancer
Recruiting2 awardsPhase 3
East Brunswick, New Jersey
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
PI3K Inhibitor
Inavolisib + Fulvestrant vs Alpelisib + Fulvestrant for Breast Cancer
Recruiting2 awardsPhase 3
Camden, New Jersey
This trial is testing two drug combinations to find out which one is better for treating a specific type of advanced breast cancer that hasn't responded to previous treatments. The drugs work by stopping cancer cells from growing and spreading.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.